Skip to main content

Table 2 Antiviral therapy related outcomes of the participants, by study arm

From: Effect of a multi-dimensional case management model on anti-retroviral therapy-related outcomes among people living with human immunodeficiency virus in Beijing, China

Indicator All Participants Participants with CD4 Less Than 350/μL
Control group (n = 1549) Intervention group (n = 3357) P-value Control group (n = 1158) Intervention group (n = 1983) P-value
Virological failure 60 (3.9) 31 (0.9) < 0.001 51 (4.4) 27 (1.4) < 0.001
Retention in care 1466 (94.6) 3159 (94.1) 0.449 1096 (94.6) 1774 (93.7) 0.290
pre-treatment interval (days)1 56 (26–253) 35 (18–133) < 0.001 48 (25–252) 35 (17–106) < 0.001
Good ART adherence 1381 (89.2) 3199 (95.3) < 0.001 949 (82.0) 1817 (96.0) < 0.001
Death (/per 100 year) 11 (0.4) 10 (0.2) < 0.001 11 (0.9) 10 (0.5) < 0.001
  1. 1pre-treatment interval, days from when a participant tested positive for HIV using a Western Blot test to when he/she initiated treatment